ORTX — Orchard Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $378.06m
- $278.24m
- $22.66m
Annual income statement for Orchard Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.08 | 2.51 | 2.6 | 1.68 | 22.7 |
| Cost of Revenue | |||||
| Gross Profit | 1.65 | 1.71 | 1.74 | 1.45 | 15.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 237 | 175 | 160 | 142 | 150 |
| Operating Profit | -235 | -173 | -157 | -140 | -127 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -230 | -166 | -153 | -144 | -153 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -230 | -163 | -152 | -145 | -151 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -230 | -163 | -152 | -145 | -151 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -230 | -163 | -152 | -145 | -151 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -26.8 | -17.5 | -15 | -1.17 | -1.17 |